PIM 激酶标靶治疗的全球市场：市场机会与临床试验的见解 (2024)

PIM 激酶由三种丝氨酸/苏氨酸蛋白激酶组成，由于其在癌症和其他疾病中的关键作用而引起了临床和商业的广泛关注。PIM 激酶作为一个有前景的治疗标靶，为开发旨在解决各种疾病领域未满足的医疗需求的标靶疗法提供了令人兴奋的前景。儘管 PIM 激酶标靶治疗市场仍处于起步阶段，但正在进行的研究工作表明这一新药物类别的治疗前景。

PIM 激酶是莫洛尼鼠白血病病毒原病毒插入位点激酶的缩写，在调节细胞存活、增殖和分化中发挥关键作用，使其成为治疗干预的有吸引力的靶点。PIM 激酶讯号传导异常与癌症、自体免疫疾病、发炎性疾病、心血管疾病和病毒性疾病有关，凸显了其广泛的治疗潜力。因此，靶向PIM激酶有望促使可应用于多种适应症的新治疗方法的开发。

PIM激酶抑制剂的开发代表了标靶治疗领域的一个重要里程碑。多年来，已经开发了多种针对 PIM 激酶的小分子抑制剂，包括 SGI-1776、MEN1703、SGI-1776、ETH-155008 和 JP11646。这些候选药物主要选择性地针对 PIM 激酶的 ATP 结合袋，抑制其催化活性并抑制参与疾病进展的下游讯号路径。SGI-1776、ETH-155008等多种药物进入临床试验凸显了人们对利用PIM激酶作为治疗标靶日益增长的兴趣，而PIM激酶抑制则是该药物走向商业化的一个重要里程碑。

儘管数量有限的 PIM 激酶抑制剂已进入临床试验，但 PIM 激酶标靶治疗领域的特点是拥有大量处于临床前开发的候选化合物。许多公司和学术机构正在积极从事研究和开发，旨在寻找具有更高功效和安全性的新型抑制剂。正在进行的临床试验正在研究PIM激酶抑制剂在多种癌症适应症（如白血病、多发性骨髓瘤和前列腺癌）以及发炎性疾病（如係统性红斑狼疮）的安全性和耐受性。

该报告调查了全球 PIM 激酶靶向治疗市场，并提供了市场概述，以及依适应症、公司、国家、细分市场、临床试验趋势以及进入市场的公司的竞争趋势进行的趋势。

目录

第一章 PIM激酶标靶治疗简介

第二章 PIM激酶标靶治疗方法

• 小分子抑制剂
• PROTAC分解器
• RNA干扰
• CRISPR/Cas9

第3章 PIM激酶标靶疗法在癌症治疗的组合

• 化学处理
• 标靶治疗
• 放射治疗
• 免疫疗法

第 4 章 PIM 激酶作为诊断与预后标记物

第五章全球PIM激酶标靶治疗研究与市场趋势（依适应症）

• 癌症
• 自体免疫疾病与发炎性疾病
• 心血管疾病
• 病毒性疾病
• 神经退行性疾病

第六章 PIM激酶疗法-公司独特的开发技术

第七章全球PIM激酶标靶治疗市场概况

第八章 PIM激酶标靶治疗分地区研究与发展趋势

• 美国
• 欧洲
• 日本
• 中国

第 9 章 PIM 激酶疗法 - FDA 依适应症指定罕见疾病

第十章 全球PIM激酶抑制剂及临床试验概况

• 爱别
• 依国家
• 依公司
• 依指示
• 患者部分

第 11 章 全球 PIM 激酶标靶治疗临床试验见解：依公司、国家、适应症和阶段分类

• 临床前
• 第一阶段
• 一期/二期
• 第二阶段

第十二章竞争格局

• Akros Pharma
• Biolexis Therapeutics
• Inflection Biosciences
• Menarini group
• Mysthera Therapeutics
• Novartis
• Shengke Pharmaceutics
• Sumitomo Pharma America

Global PIM Kinase Targeted Therapies Market Opportunity & Clinical Trials Insight 2024 Report Highlights:

• PIM Kinase Targeted Therapies In Clinical Trials: > 10 Therapies
• PIM Kinase Targeted Therapies Clinical Trials Insight By Company, Country, Indication & Phase
• USA Dominating PIM Kinase Targeted Therapies Clinical Trials Landscape: > 5 Therapies
• Role Of PIM Kinases as Diagnostic & Prognostic Markers
• FDA Orphan Designation To PIM Kinase Therapies By indication
• Proprietary Development Technologies By Companies

PIM kinases, comprising three serine/threonine protein kinases, have garnered significant attention in both clinical and commercial spheres due to their pivotal roles in cancer and other disease indications. As promising therapeutic targets, PIM kinases offer exciting prospects for the development of targeted therapies aimed at addressing unmet medical needs across various diseases area. Though the market of PIM kinase targeted therapies is still in a budding phase, ongoing research efforts point towards a fruitful future for this emerging drug class.

PIM kinases, standing for Proviral Insertion Site in Moloney Murine Leukemia Virus kinases, play crucial roles in regulating cell survival, proliferation and differentiation, making them attractive targets for therapeutic intervention. Dysregulated PIM kinase signaling has been implicated in cancer, autoimmune disorders, inflammatory conditions, cardiovascular diseases and viral diseases, highlighting their broad therapeutic potential. As such, targeting PIM kinases holds promise for development of novel treatments with potential applications across a diverse range of indications.

The development of PIM kinases inhibitors represents a significant milestone in the field of targeted therapy. Over the years, several small molecule inhibitors targeting PIM kinases have been developed, with notable examples including SGI-1776, MEN1703, SGI-1776, ETH-155008, JP11646. These candidates majorly target the ATP-binding pocket of PIM kinases selectively, inhibiting their catalytic activity and disrupting downstream signaling pathways implicated in disease progression. The advancement of some of these such as SGI-1776, ETH-155008 into clinical trials underscores the growing interest in exploiting PIM kinases as therapeutic targets and represents a key milestone in moving PIM kinase inhibitors towards commercialization.

While only a limited number of PIM kinase inhibitors have progressed to clinical trials, the landscape of PIM kinase targeted therapies is characterized by a robust pipeline of candidates in preclinical development. Numerous companies and academic institutions are actively engaged in research and development efforts aimed at identifying novel inhibitors with improved efficacy and safety profiles. Ongoing clinical trials are evaluating the safety, tolerability and efficacy of PIM kinase inhibitors in various cancer indications, including leukemia, multiple myeloma and prostate cancer, as well as inflammatory conditions like systemic lupus erythematosus.

Collaborations between pharmaceutical companies, academic institutions and research hospitals have been instrumental in driving progress in the development of PIM kinase targeted therapies. Academic institutions like University of Arizona, University of Leipzig, Ludwig Maximilians University Munich, University of Alabama, Ohio State University, Medical University of South Carolina and Pusan National University have over the years contributed valuable insights into the underlying biology of PIM kinases and their role in disease pathogenesis. Companies on the other hand bring expertise in drug discovery and development while hospitals serve as places to conduct clinical trials and additional research.

The development of RF-1302, a novel dual inhibitor of PIM-1 and FLT3 kinases, by the Chinese Academy of Medical Science and Tianjin Medical University General Hospital in partnership with Ruifu Therapeutics, serves as an example of this. The candidate is presently undergoing preclinical studies to treat acute myeloid leukemia. This kind of collaborative spirit encourages innovation and speeds up the translation of fundamental research discoveries into treatment interventions that have practical application. Companies and academic institutions can accelerate the commercialization of PIM kinase targeted therapies and optimize their potential by utilizing complementary capabilities and resources.

The market for PIM kinase targeted therapies looks to have a promising future with lots of scope to grow. Structure-based drug design and high-throughput screening are two examples of how drug discovery technologies are progressing and could lead to the development of new PIM kinase inhibitors with better potency and selectivity. Furthermore, the development of precision medicine strategies and biomarker-driven methodologies may make it possible to implement more individualized and focused treatment plans, improving the therapeutic utility of PIM kinase targeted therapies.

Additionally, novel treatment approaches may be discovered as a result of our growing understanding of PIM kinase biology and its significance in the pathophysiology of disease. PIM kinase targeted therapy development will be accelerated by industry-academia collaborations, which will ultimately benefit patients by offering more individualized and effective treatment alternatives. Because of this, the market for PIM kinase targeted therapies is anticipated to experience rapid expansion and innovation in the years to come, presenting intriguing prospects for players in the pharmaceutical sector.

Table of Contents

1. Introduction to PIM Kinase Targeted Therapy

• 1.1 Overview
• 1.2 History, Development & Evolution

2. PIM Kinase Targeted Therapy Approaches

• 2.1 Small Molecule Inhibitors
• 2.2 PROTAC Degraders
• 2.3 RNA Interference
• 2.4 CRISPR/Cas9

3. PIM Kinase Targeted Therapy Combinations for Cancer Treatment

• 3.1 Chemotherapy
• 3.2 Targeted Therapies
• 3.3 Radiotherapy
• 3.4 Immunotherapy

4. PIM Kinases as Diagnostic & Prognostic Markers

5. Global PIM Kinase Targeted Therapies Research & Market Trends by Indication

• 5.1 Cancer
• 5.2 Autoimmune & Inflammatory Disorders
• 5.3 Cardiovascular Diseases
• 5.4 Viral Diseases
• 5.5 Neurodegenerative Diseases

6. PIM Kinase Therapies - Proprietary Development Technologies By Companies

7. Global PIM Kinase Targeted Therapies Market Overview

• 7.1 Current Market Scenario
• 7.2 Future Commercialization Outlook
• 7.3 Favorable Developmental Parameters
• 7.4 Key Challenges & Restraints

8. PIM Kinase Targeted Therapies Research & Development Trends By Region

• 8.1 US
• 8.2 Europe
• 8.3 Japan
• 8.4 China

9. PIM Kinase Therapies - FDA Orphan Designation By Indication

10. Global PIM Kinase Inhibitor Clinical Trials Overview

• 10.1 By Phase
• 10.2 By Country
• 10.3 By Company
• 10.4 By Indication
• 10.5 Patient Segment

11. Global PIM Kinase Targeted Therapies Clinical Trials Insight By Company, Country, Indication & Phase

• 11.1 Preclinical
• 11.2 Phase I
• 11.3 Phase I/II
• 11.4 Phase II

12. Competitive Landscape

• 12.1 Akros Pharma
• 12.2 Biolexis Therapeutics
• 12.3 Inflection Biosciences
• 12.4 Menarini group
• 12.5 Mysthera Therapeutics
• 12.6 Novartis
• 12.7 Shengke Pharmaceutics
• 12.8 Sumitomo Pharma America

List of Figures

• Figure 1-1: PIM Kinase Targeted Therapies - Developmental Milestones
• Figure 2-1: PIM Kinase Targeted Therapy - Current Approaches
• Figure 2-2: PIM Kinase Small Molecule Inhibition - Future Opportunities
• Figure 2-3: PROTACs - Advantages
• Figure 2-4: PROTACs - Future Opportunities
• Figure 2-5: CRISPR/Cas9 - Benefits as a Therapeutic Modality
• Figure 2-6: Effects of CRISPR/Cas9-mediated DSB repair mechanism on PIM Kinase activity
• Figure 3-1: Combination of PIM Targeted Therapies & Chemotherapy - Benefits
• Figure 3-2: Combination of PIM Targeted therapies & Immunotherapy - Benefits
• Figure 5-1: PIM Kinases - Functions in Viral Infections
• Figure 6-1: Biolexis Therapeutics - MolecuLern Process
• Figure 7-1: PIM Kinase Targeted Therapies - Future Opportunities
• Figure 7-2: Global PIM Kinase Targeted Therapies Market - Drivers & Opportunities
• Figure 7-3: Global PIM Kinase Targeted Therapies Market - Challenges & Restraints
• Figure 9-1: Regulatory Designations - Benefits
• Figure 10-1: Global - PIM Kinase Targeted Therapies Clinical Trials By Phase (Numbers), 2024
• Figure 10-2: Global - PIM Kinase Targeted Therapies Clinical Trials By Country (Numbers), 2024
• Figure 10-3: Global - PIM Kinase Targeted Therapies Clinical Trials By Company (Numbers), 2024
• Figure 10-4: Global - PIM Kinase Targeted Therapies Clinical Trials By Indication (Numbers), 2024
• Figure 10-5: Global - PIM Kinase Targeted Therapies Clinical Trials By Patient Segment (Numbers), 2024

List of Tables

• Table 5-1: Cancer - PIM inhibitors in Clinical Development
• Table 5-2: Autoimmune & Inflammatory Disorders - PIM inhibitors in Clinical Development
• Table 5-3: Cardiovascular Diseases - PIM inhibitors in Clinical Development
• Table 9-1: PIM Kinase Therapies - FDA Orphan Designation By Indication